These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2166654)

  • 1. Effects of a long-acting somatostatin analogue on pituitary-adrenocortical secretion in normal human subjects.
    Itoh S; Tanaka K; Kumage M; Shimizu N
    Endocrinol Jpn; 1990 Feb; 37(1):131-9. PubMed ID: 2166654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of hypothalamo-pituitary-adrenocortical function in children by human corticotropin-releasing hormone (MCI-028) test.
    Tanaka T; Hibi I; Shimizu N; Imura H; Tanaka K; Fukata J; Fujieda K; Ichimura T; Kuribayashi T; Ito K
    Endocr J; 1993 Oct; 40(5):581-9. PubMed ID: 7951524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome.
    Ghigo E; Arvat E; Ramunni J; Colao A; Gianotti L; Deghenghi R; Lombardi G; Camanni F
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2439-44. PubMed ID: 9253314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of somatostatin-octreotide on secretion of adrenocorticotropin, cortisol and neuro-hypophyseal hormones in acromegaly].
    Julesz J; Vecsernyés M; Szász A; Szabados E; Tóth I; Laczi F
    Orv Hetil; 1998 Dec; 139(51):3071-4. PubMed ID: 9914727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery from glucocorticoid inhibition of the responses to corticotrophin-releasing hormone.
    Watson AC; Rosenfield RL; Fang VS
    Clin Endocrinol (Oxf); 1988 May; 28(5):471-7. PubMed ID: 2850875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticotropin releasing hormone: relevance to normal physiology and to the pathophysiology and differential diagnosis of hypercortisolism and adrenal insufficiency.
    Gold PW; Kling MA; Khan I; Calabrese JR; Kalogeras K; Post RM; Avgerinos PC; Loriaux DL; Chrousos GP
    Adv Biochem Psychopharmacol; 1987; 43():183-200. PubMed ID: 3035886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of pulsatile human corticotropin-releasing hormone administration on the adrenal insufficiency that follows cure of Cushing's disease.
    Avgerinos PC; Nieman LK; Oldfield EH; Loughlin T; Barnes KM; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1989 May; 68(5):912-6. PubMed ID: 2541160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation by peptide histidine methionine (PHM) of adrenocorticotropin secretion in patients with Cushing's disease: a comparison with the effect of vasoactive intestinal peptide (VIP) and a study on the effect of combined administration of corticotropin-releasing hormone with PHM or VIP.
    Watanobe H; Tamura T
    J Clin Endocrinol Metab; 1994 Jun; 78(6):1372-7. PubMed ID: 8200939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pituitary-adrenal response to CRF-41 is unaltered by intravenous somatostatin in normal subjects.
    Stafford PJ; Kopelman PG; Davidson K; McLoughlin L; White A; Rees LH; Besser GM; Coy DH; Grossman A
    Clin Endocrinol (Oxf); 1989 Jun; 30(6):661-6. PubMed ID: 2574084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ability of corticotropin releasing hormone to stimulate cortisol secretion independent from pituitary adrenocorticotropin.
    Fehm HL; Holl R; Späth-Schwalbe E; Born J; Voigt KH
    Life Sci; 1988; 42(6):679-86. PubMed ID: 2828799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans.
    Dorin RI; Ferries LM; Roberts B; Qualls CR; Veldhuis JD; Lisansky EJ
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3883-91. PubMed ID: 8923833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response effects of exogenous pulsatile human corticotropin-releasing hormone on adrenocorticotropin, cortisol, and gonadotropin concentrations in agonadal women.
    Thomas MA; Rebar RW; LaBarbera AR; Pennington EJ; Liu JH
    J Clin Endocrinol Metab; 1991 Jun; 72(6):1249-54. PubMed ID: 1851183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide exerts different effects in vivo and in vitro in Cushing's disease.
    Stalla GK; Brockmeier SJ; Renner U; Newton C; Buchfelder M; Stalla J; Müller OA
    Eur J Endocrinol; 1994 Feb; 130(2):125-31. PubMed ID: 8130885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of plasma osmolality on pituitary-adrenal responses to corticotropin-releasing hormone and atrial natriuretic peptide changes in central diabetes insipidus.
    Elias LL; Antunes-Rodrigues J; Elias PC; Moreira AC
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1243-7. PubMed ID: 9100602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans.
    Arvat E; Maccagno B; Ramunni J; Di Vito L; Broglio F; Deghenghi R; Camanni F; Ghigo E
    Neuroendocrinology; 1997 Dec; 66(6):432-8. PubMed ID: 9430449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response relationships between plasma adrenocorticotropin (ACTH), cortisol, aldosterone, and 18-hydroxycorticosterone after injection of ACTH-(1-39) or human corticotropin-releasing hormone in man.
    Oelkers W; Boelke T; Bähr V
    J Clin Endocrinol Metab; 1988 Jan; 66(1):181-6. PubMed ID: 2826525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans.
    Grottoli S; Maccagno B; Ramunni J; Di Vito L; Giordano R; Gianotti L; DeStefanis S; Camanni F; Ghigo E; Arvat E
    J Endocrinol Invest; 2002 May; 25(5):420-5. PubMed ID: 12035937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of human corticotropin-releasing hormone on somatostatin secretion in depressed patients and controls.
    Lesch KP; Widerlöv E; Ekman R; Laux G; Rupprecht R; Schulte HM; Beckmann H
    J Neural Transm; 1989; 75(2):111-8. PubMed ID: 2563752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.
    Ambrosi B; Bochicchio D; Fadin C; Colombo P; Faglia G
    J Endocrinol Invest; 1990 Mar; 13(3):257-61. PubMed ID: 1973178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation.
    Bertagna X; Escourolle H; Pinquier JL; Coste J; Raux-Demay MC; Perles P; Silvestre L; Luton JP; Strauch G
    J Clin Endocrinol Metab; 1994 Feb; 78(2):375-80. PubMed ID: 8106625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.